考虑在异基因干细胞移植后接种 HPV 疫苗。
Time to consider HPV vaccination after allogeneic stem cell transplantation.
机构信息
Long- Term Follow-up Transplant Clinic (LTTC), Hematology and Stem Cell Transplantation Section, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232-5505, USA.
出版信息
Biol Blood Marrow Transplant. 2010 Aug;16(8):1033-6. doi: 10.1016/j.bbmt.2010.03.007. Epub 2010 Mar 17.
Abstract
Squamous cell carcinoma (SCC) is among the most common secondary cancers after allogeneic stem cell transplantation (allo-SCT). Several types of human papillomavirus (HPV) are causally linked with SCC of the genital tract and head and neck, and the incidence of these cancers is higher among immunosuppressed patients compared to immunocompetent patients. In June 2006, a quadrivalent HPV vaccine was approved by the Food and Drug Administration (FDA) for females aged 9 to 26 years to prevent cervical warts and vulvar, vaginal, and cervical cancer. FDA approval was granted in October 2009 for males aged 9 to 26 years to prevent genital warts. The quadrivalent HPV vaccine is now available for off-label use, and may be beneficial to patients after allo-SCT. It is time to evaluate the immunogenicity and efficacy in preventing HPV-related squamous cell carcinoma in this population.
摘要
鳞状细胞癌 (SCC) 是异基因造血干细胞移植 (allo-SCT) 后最常见的继发性癌症之一。几种类型的人乳头瘤病毒 (HPV) 与生殖道、头颈部 SCC 有因果关系，与免疫功能正常的患者相比，免疫抑制患者的这些癌症发病率更高。2006 年 6 月，食品和药物管理局 (FDA) 批准了一种四价 HPV 疫苗，用于预防 9 至 26 岁女性的宫颈疣、外阴、阴道和宫颈癌。2009 年 10 月，FDA 批准 9 至 26 岁男性用于预防生殖器疣。目前四价 HPV 疫苗已被批准用于超适应证使用，对 allo-SCT 后的患者可能有益。现在是评估该人群 HPV 相关鳞状细胞癌的免疫原性和疗效的时候了。
相似文献
1
Time to consider HPV vaccination after allogeneic stem cell transplantation.
Biol Blood Marrow Transplant. 2010 Aug;16(8):1033-6. doi: 10.1016/j.bbmt.2010.03.007. Epub 2010 Mar 17.
2
Can routine posttransplant HPV vaccination prevent commonly occurring epithelial cancers after allogeneic stem cell transplantation?
Clin Cancer Res. 2009 Apr 1;15(7):2219-21. doi: 10.1158/1078-0432.CCR-08-3099. Epub 2009 Mar 17.
3
Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.
Cochrane Database Syst Rev. 2019 Nov 22;2019(11):CD013479. doi: 10.1002/14651858.CD013479.
4
Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.
Drugs. 2010 Dec 24;70(18):2449-74. doi: 10.2165/11204920-000000000-00000.
5
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24.
6
FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP).
MMWR Morb Mortal Wkly Rep. 2010 May 28;59(20):630-2.
7
Prophylactic HPV vaccination: past, present, and future.
Epidemiol Infect. 2016 Feb;144(3):449-68. doi: 10.1017/S0950268815002198. Epub 2015 Oct 2.
8
Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
BioDrugs. 2011 Oct 1;25(5):339-43. doi: 10.2165/11205060-000000000-00000.
9
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Cochrane Database Syst Rev. 2018 May 9;5(5):CD009069. doi: 10.1002/14651858.CD009069.pub3.
10
A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US.
Cancer. 2008 Nov 15;113(10 Suppl):2995-3003. doi: 10.1002/cncr.23763.
引用本文的文献
1
Sexual and Emotional Health after Allogeneic Hematopoietic Cell Transplantation: A Comprehensive Review and Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).
J Clin Med. 2022 Feb 23;11(5):1196. doi: 10.3390/jcm11051196.
2
Optimal Delivery of Follow-Up Care After Allogeneic Hematopoietic Stem-Cell Transplant: Improving Patient Outcomes with a Multidisciplinary Approach.
J Blood Med. 2020 May 15;11:141-162. doi: 10.2147/JBM.S206027. eCollection 2020.
3
The management of gynecological complications in long-term survivors after allogeneic hematopoietic cell transplantation-a single-center real-life experience.
Ann Hematol. 2020 Jun;99(6):1361-1368. doi: 10.1007/s00277-020-04034-1. Epub 2020 Apr 28.
4
The management of numerous carcinomatous sequelae of human papilloma virus in an allogeneic stem cell transplant patient with chronic graft versus host disease.
JAAD Case Rep. 2019 Jan 28;5(2):162-166. doi: 10.1016/j.jdcr.2018.11.010. eCollection 2019 Feb.
5
Human papilloma virus-specific T cells can be generated from naïve T cells for use as an immunotherapeutic strategy for immunocompromised patients.
Cytotherapy. 2018 Mar;20(3):385-393. doi: 10.1016/j.jcyt.2017.11.010. Epub 2018 Jan 10.
6
Incomplete vaccination coverage in European children with end-stage kidney disease prior to renal transplantation.
Pediatr Nephrol. 2018 Feb;33(2):341-350. doi: 10.1007/s00467-017-3776-3. Epub 2017 Oct 5.
7
Late effects of blood and marrow transplantation.
Haematologica. 2017 Apr;102(4):614-625. doi: 10.3324/haematol.2016.150250. Epub 2017 Feb 23.
8
Clinical management of genital chronic GvHD.
Bone Marrow Transplant. 2017 Jun;52(6):803-810. doi: 10.1038/bmt.2016.315. Epub 2017 Jan 9.
9
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.
Biol Blood Marrow Transplant. 2017 Jun;23(6):870-881. doi: 10.1016/j.bbmt.2016.10.001. Epub 2016 Oct 14.
10
Secondary solid cancer screening following hematopoietic cell transplantation.
Bone Marrow Transplant. 2015 Aug;50(8):1013-23. doi: 10.1038/bmt.2015.63. Epub 2015 Mar 30.
本文引用的文献
1
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.
N Engl J Med. 2009 Nov 5;361(19):1838-47. doi: 10.1056/NEJMoa0810097.
2
Risk of human papillomavirus-associated cancers among persons with AIDS.
J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30. doi: 10.1093/jnci/djp205. Epub 2009 Jul 31.
3
Viral-associated nonmelanoma skin cancers: a review.
Am J Dermatopathol. 2009 Aug;31(6):561-73. doi: 10.1097/DAD.0b013e3181a58234.
4
Can routine posttransplant HPV vaccination prevent commonly occurring epithelial cancers after allogeneic stem cell transplantation?
Clin Cancer Res. 2009 Apr 1;15(7):2219-21. doi: 10.1158/1078-0432.CCR-08-3099. Epub 2009 Mar 17.
5
HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women.
Cancer. 2008 Nov 15;113(10 Suppl):3036-46. doi: 10.1002/cncr.23764.
6
Solid cancers after allogeneic hematopoietic cell transplantation.
Blood. 2009 Jan 29;113(5):1175-83. doi: 10.1182/blood-2008-05-158782. Epub 2008 Oct 29.
7
Increased risk of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation--implications for screening and HPV vaccination.
Biol Blood Marrow Transplant. 2008 Sep;14(9):1072-1075. doi: 10.1016/j.bbmt.2008.07.005.
8
Prophylactic HPV vaccines: new interventions for cancer control.
Vaccine. 2008 Nov 18;26(49):6244-57. doi: 10.1016/j.vaccine.2008.07.056. Epub 2008 Aug 9.
9
Human papillomavirus vaccines in HIV-positive men and women.
Curr Opin Oncol. 2007 Sep;19(5):470-5. doi: 10.1097/CCO.0b013e3282c8c8fc.
10
Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study.
Blood. 2007 Nov 15;110(10):3784-92. doi: 10.1182/blood-2007-03-082933. Epub 2007 Aug 1.
Zotero 插件